Cargando…

Correlation between GenoType MTBDRplus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance

BACKGROUND: The purpose of this study was to analyze the relationship between the gene mutation patterns by the GenoType MTBDRplus (MTBDRplus) assay and the phenotypic drug susceptibility test (pDST) results of isoniazid (INH) and prothionamide (Pto). METHODS: A total of 206 patients whose MTBDRplus...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Joo Hee, Jo, Kyung-Wook, Shim, Tae Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Tuberculosis and Respiratory Diseases 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435929/
https://www.ncbi.nlm.nih.gov/pubmed/30302956
http://dx.doi.org/10.4046/trd.2018.0027
_version_ 1783406727585071104
author Lee, Joo Hee
Jo, Kyung-Wook
Shim, Tae Sun
author_facet Lee, Joo Hee
Jo, Kyung-Wook
Shim, Tae Sun
author_sort Lee, Joo Hee
collection PubMed
description BACKGROUND: The purpose of this study was to analyze the relationship between the gene mutation patterns by the GenoType MTBDRplus (MTBDRplus) assay and the phenotypic drug susceptibility test (pDST) results of isoniazid (INH) and prothionamide (Pto). METHODS: A total of 206 patients whose MTBDRplus assay results revealed katG or inhA mutations were enrolled in the study. The pDST results were compared to mutation patterns on the MTBDRplus assay. RESULTS: The katG and inhA mutations were identified in 68.0% and 35.0% of patients, respectively. Among the 134 isolated katG mutations, three (2.2%), 127 (94.8%) and 11 (8.2%) were phenotypically resistant to low-level INH, high-level INH, and Pto, respectively. Among the 66 isolated inhA mutations, 34 (51.5%), 18 (27.3%) and 21 (31.8%) were phenotypically resistant to low-level INH, high-level INH, and Pto, respectively. Of the 34 phenotypic Pto resistant isolates, 21 (61.8%), 11 (32.4%), and two (5.9%) had inhA, katG, and both gene mutations. CONCLUSION: It is noted that Pto may still be selected as one of the appropriate multidrug-resistant tuberculosis regimen, although inhA mutation is detected by the MTBDRplus assay until pDST confirms a Pto resistance. The reporting of detailed mutation patterns of the MTBDRplus assay may be important for clinical practice, rather than simply presenting resistance or susceptibility test results.
format Online
Article
Text
id pubmed-6435929
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Korean Academy of Tuberculosis and Respiratory Diseases
record_format MEDLINE/PubMed
spelling pubmed-64359292019-04-02 Correlation between GenoType MTBDRplus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance Lee, Joo Hee Jo, Kyung-Wook Shim, Tae Sun Tuberc Respir Dis (Seoul) Original Article BACKGROUND: The purpose of this study was to analyze the relationship between the gene mutation patterns by the GenoType MTBDRplus (MTBDRplus) assay and the phenotypic drug susceptibility test (pDST) results of isoniazid (INH) and prothionamide (Pto). METHODS: A total of 206 patients whose MTBDRplus assay results revealed katG or inhA mutations were enrolled in the study. The pDST results were compared to mutation patterns on the MTBDRplus assay. RESULTS: The katG and inhA mutations were identified in 68.0% and 35.0% of patients, respectively. Among the 134 isolated katG mutations, three (2.2%), 127 (94.8%) and 11 (8.2%) were phenotypically resistant to low-level INH, high-level INH, and Pto, respectively. Among the 66 isolated inhA mutations, 34 (51.5%), 18 (27.3%) and 21 (31.8%) were phenotypically resistant to low-level INH, high-level INH, and Pto, respectively. Of the 34 phenotypic Pto resistant isolates, 21 (61.8%), 11 (32.4%), and two (5.9%) had inhA, katG, and both gene mutations. CONCLUSION: It is noted that Pto may still be selected as one of the appropriate multidrug-resistant tuberculosis regimen, although inhA mutation is detected by the MTBDRplus assay until pDST confirms a Pto resistance. The reporting of detailed mutation patterns of the MTBDRplus assay may be important for clinical practice, rather than simply presenting resistance or susceptibility test results. The Korean Academy of Tuberculosis and Respiratory Diseases 2019-04 2018-09-28 /pmc/articles/PMC6435929/ /pubmed/30302956 http://dx.doi.org/10.4046/trd.2018.0027 Text en Copyright©2019. The Korean Academy of Tuberculosis and Respiratory Diseases http://creativecommons.org/licenses/by-nc/4.0/ It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Original Article
Lee, Joo Hee
Jo, Kyung-Wook
Shim, Tae Sun
Correlation between GenoType MTBDRplus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance
title Correlation between GenoType MTBDRplus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance
title_full Correlation between GenoType MTBDRplus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance
title_fullStr Correlation between GenoType MTBDRplus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance
title_full_unstemmed Correlation between GenoType MTBDRplus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance
title_short Correlation between GenoType MTBDRplus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance
title_sort correlation between genotype mtbdrplus assay and phenotypic susceptibility test for prothionamide in patients with genotypic isoniazid resistance
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435929/
https://www.ncbi.nlm.nih.gov/pubmed/30302956
http://dx.doi.org/10.4046/trd.2018.0027
work_keys_str_mv AT leejoohee correlationbetweengenotypemtbdrplusassayandphenotypicsusceptibilitytestforprothionamideinpatientswithgenotypicisoniazidresistance
AT jokyungwook correlationbetweengenotypemtbdrplusassayandphenotypicsusceptibilitytestforprothionamideinpatientswithgenotypicisoniazidresistance
AT shimtaesun correlationbetweengenotypemtbdrplusassayandphenotypicsusceptibilitytestforprothionamideinpatientswithgenotypicisoniazidresistance